Comparative Efficacy of Neuraminidase-Specific and Conventional Influenza Virus Vaccines in Induction of Antibody to Neuraminidase in Humans
Identifieur interne : 002B30 ( Main/Exploration ); précédent : 002B29; suivant : 002B31Comparative Efficacy of Neuraminidase-Specific and Conventional Influenza Virus Vaccines in Induction of Antibody to Neuraminidase in Humans
Auteurs : Edwin D. Kilbourne [États-Unis]Source :
- Journal of Infectious Diseases [ 0022-1899 ] ; 1976.
Abstract
Groups of college students received either conventional A/England/42/72 (H3N2) vaccine (X-37), an antigenic hybrid (HeqlN2) vaccine (X-38) containing the same neuraminidase (and thus effectively neuraminidase-monospecific), or a placebo injection. The vaccines contained 798 and 643 chick cell-agglutinating units per dose, respectively, and equivalent immunogenic units of N2 as defined in antigenic extinction tests in rabbits. All subjects had antibody to N2 before immunization, and mean initial titers were comparable in both vaccine groups. Homotypic hemagglutination- inhibition response to vaccine hemagglutinin was slightly more frequent (77%) but of lower magnitude in the students vaccinated with X-38 than in those vaccinated with X-37. Significant antibody response to N2 was observed in 25% of those vaccinated with X-37 and in 69% of those vaccinated with X-38. Mean antibody response to N2 was twofold greater in those vaccinated with X-38. Heterotypic hemagglutination-inhibition was seen in 56% of those receiving X-38 vaccine. In preliminary plaque-inhibition titrations this heterotypic antibody did not have neutralizing activity. Testing of antibody response to N2 with earlier neuraminidase antigens demonstrated “original antigenic sin” from earlier priming. The superiority of the “neuraminidase-specific” X-38 (HeqI N2) vaccine as an immunogen for antibody to neuraminidase may reflect different processing of N2 when it is associated with a hemagglutinin to which the study population has not been previously exposed.
Url:
DOI: 10.1093/infdis/134.4.384
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001235
- to stream Istex, to step Curation: 001235
- to stream Istex, to step Checkpoint: 001697
- to stream Main, to step Merge: 002D00
- to stream Main, to step Curation: 002B30
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Comparative Efficacy of Neuraminidase-Specific and Conventional Influenza Virus Vaccines in Induction of Antibody to Neuraminidase in Humans</title><author wicri:is="90%"><name sortKey="Kilbourne, Edwin D" sort="Kilbourne, Edwin D" uniqKey="Kilbourne E" first="Edwin D." last="Kilbourne">Edwin D. Kilbourne</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:042ECE52026553128116BCFE54E09D9875B359CE</idno><date when="1976" year="1976">1976</date><idno type="doi">10.1093/infdis/134.4.384</idno><idno type="url">https://api.istex.fr/ark:/67375/HXZ-7NL1VJP2-2/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001235</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001235</idno><idno type="wicri:Area/Istex/Curation">001235</idno><idno type="wicri:Area/Istex/Checkpoint">001697</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001697</idno><idno type="wicri:doubleKey">0022-1899:1976:Kilbourne E:comparative:efficacy:of</idno><idno type="wicri:Area/Main/Merge">002D00</idno><idno type="wicri:Area/Main/Curation">002B30</idno><idno type="wicri:Area/Main/Exploration">002B30</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Comparative Efficacy of Neuraminidase-Specific and Conventional Influenza Virus Vaccines in Induction of Antibody to Neuraminidase in Humans<ref type="fn" target="#fn1"></ref><ref type="fn" target="#fn2"></ref></title><author wicri:is="90%"><name sortKey="Kilbourne, Edwin D" sort="Kilbourne, Edwin D" uniqKey="Kilbourne E" first="Edwin D." last="Kilbourne">Edwin D. Kilbourne</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>From the Department of Microbiology, Mount Sinai School of Medicine of the City University of New York, Buffalo</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Infectious Diseases</title><title level="j" type="abbrev">J Infect Dis.</title><idno type="ISSN">0022-1899</idno><idno type="eISSN">1537-6613</idno><imprint><publisher>The University of Chicago Press</publisher><date when="1976-10">1976</date><biblScope unit="vol">134</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="384">384</biblScope><biblScope unit="page" to="394">394</biblScope></imprint><idno type="ISSN">0022-1899</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-1899</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Groups of college students received either conventional A/England/42/72 (H3N2) vaccine (X-37), an antigenic hybrid (HeqlN2) vaccine (X-38) containing the same neuraminidase (and thus effectively neuraminidase-monospecific), or a placebo injection. The vaccines contained 798 and 643 chick cell-agglutinating units per dose, respectively, and equivalent immunogenic units of N2 as defined in antigenic extinction tests in rabbits. All subjects had antibody to N2 before immunization, and mean initial titers were comparable in both vaccine groups. Homotypic hemagglutination- inhibition response to vaccine hemagglutinin was slightly more frequent (77%) but of lower magnitude in the students vaccinated with X-38 than in those vaccinated with X-37. Significant antibody response to N2 was observed in 25% of those vaccinated with X-37 and in 69% of those vaccinated with X-38. Mean antibody response to N2 was twofold greater in those vaccinated with X-38. Heterotypic hemagglutination-inhibition was seen in 56% of those receiving X-38 vaccine. In preliminary plaque-inhibition titrations this heterotypic antibody did not have neutralizing activity. Testing of antibody response to N2 with earlier neuraminidase antigens demonstrated “original antigenic sin” from earlier priming. The superiority of the “neuraminidase-specific” X-38 (HeqI N2) vaccine as an immunogen for antibody to neuraminidase may reflect different processing of N2 when it is associated with a hemagglutinin to which the study population has not been previously exposed.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Kilbourne, Edwin D" sort="Kilbourne, Edwin D" uniqKey="Kilbourne E" first="Edwin D." last="Kilbourne">Edwin D. Kilbourne</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B30 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002B30 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:042ECE52026553128116BCFE54E09D9875B359CE
|texte= Comparative Efficacy of Neuraminidase-Specific and Conventional Influenza Virus Vaccines in Induction of Antibody to Neuraminidase in Humans
}}
| This area was generated with Dilib version V0.6.33. |  |